drugset / Trial / NCT05909826
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
NaSingle-groupOpen-labelTreatment
Summary
This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2027-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |
| Background | Carfilzomib | Other / unclassified | 70 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |